- Eli Lilly’s weight loss drug Zepbound cuts heart failure risks in late-stage study CNBC
- Eli Lilly’s tirzepatide cuts heart failure risks, company says NBC News
- Live news: 10-year Treasury yield dips under 4% as traders bet on three Fed rate cuts in 2024 Financial Times
- Video Study suggests Zepbound can help patients dealing with heart failure ABC News
- Lilly’s tirzepatide successful in phase 3 study showing benefit in adults with heart failure with preserved ejection fraction and obesity Investors | Eli Lilly and Company
